The third phase of trials of the mRNA-1273 coronavirus vaccine of the American company Moderna showed the effectiveness of the drug at 94.5 percent. This was reported on the developer's website with reference to data from experts from the Data Security Monitoring Council (DSMB).
More than 30 thousand people took part in the tests, 95 people were infected with coronavirus at the intermediate stage. It is noted that 90 cases were in the control group, whose members were injected with placebo. Thus, among those who actually received the COVID-19 vaccine, only five people became infected. Most of the study participants underwent vaccination without any noticeable side effects.
Moderna CEO Stefan Bansel announced a turning point in drug development. “This is a turning point in the development of our vaccine. The result of the interim analysis gave us the first clinical confirmation that our vaccine can prevent COVID-19 disease, including severe disease, ”he said.
Earlier, the American pharmaceutical company Pfizer and its German biotechnology partner BioNTech announced a successful third phase of clinical trials of the BNT162b2 coronavirus vaccine. The third phase demonstrated the effectiveness of the vaccine in more than 90 percent of the subjects.
In total, Europe has reserved more than one billion doses of potential coronavirus vaccines. They are being developed by companies such as AstraZeneca, Sanofi and Johnson & Johnson. An EU spokesman said negotiations are underway with CureVac, Moderna and Pfizer.
